US EditionEU Commission fines Teva $500 million for trying to stop rival’s multiple sclerosis drug
- The European Commission fined Teva more than 460 million euros, or $500 million, for improperly seeking to protect its multiple sclerosis drug patent and disparaging a rival's competing medicine.
- Teva used a "disparagement campaign" against Synthon, which had an authorized glatiramer acetate drug, to "sow doubt on the safety, efficacy and therapeutic equivalence" of the rival product.
- Teva disagreed with the decision, claiming it was based on "legal theories... that are extreme, untested, and factually unsupported," and must pay the fine and avoid similar actions.
26 Articles
26 Articles
The EU Commission has fined the pharmaceutical company Teva 462.6 million euros for abusing the patent system to extend the exclusivity of its drug Copaxone, used to treat multiple sclerosis. The abuse of the dominant position has delayed the entry of a competing medicine and, according to the EU Antistrust, has caused damage to the company 'blocked' in the markets of Belgium, Italy, Germany, the Netherlands, the Czech Republic, Spain and Poland…
EU fines Israeli drug-maker Teva $500 million over patent abuse in MS drug market
Teva “spread information contradicted by health authorities’ findings, seeking to sow doubt on the safety, efficacy and therapeutic equivalence of the rival product,” the EU Commission said.
The Israeli company Teva is said to have exploited its market power to the detriment of people suffering from multiple sclerosis. Brussels is demanding a large fine for this. Teva denies the allegations.
The European Commission has fined the Israeli pharmaceutical group Teva 426.6 million euros for what it says; "abuse of dominance" for his multiple sclerosis drug, Copaxone.
Coverage Details
Bias Distribution
- 56% of the sources lean Left
To view factuality data please Upgrade to Premium
